Revenue

9 Months Ended

Sep. 30, 2021

Disaggregation Of Revenue [Abstract]

Revenue

11. Revenue

The following table provides information about disaggregated revenue by product mix and service (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Product revenue:
ANNOVERA	$	11,807	$	6,419	$	30,112	$	10,527
IMVEXXY		8,016		6,841		24,866		18,319
BIJUVA		3,298		1,646		7,899		4,110
Prescription vitamin		1,348		2,436		4,225		7,338
Product revenue, net		24,469		17,342		67,102		40,294
License revenue		937		2,000		1,171		2,000
Total revenue, net	$	25,406	$	19,342	$	68,273	$	42,294

We have entered into a license and supply agreement (the “Knight License Agreement”), with Knight Therapeutics, Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. We also have entered into a licensing and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY and BIJUVA for human use outside of the U.S., except for Canada and Israel.

For the three months and nine months ended September 30, 2021, we recorded BIJUVA sales of $0.7 million made through the Theramex License Agreement. As of September 30, 2021, no BIJUVA sales have been made through the Knight License Agreement. Additionally, as of September 30, 2021, no IMVEXXY sales have been made through either of the licensing agreements.